Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 23062-06-8
2. Fasedienol
3. Aloradine
4. 4,16-androstadien-3-beta-ol
5. 4,16-androstadien-3beta-ol
6. Dtw1nj7ijh
7. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
8. Androsta-4,16-dien-3-ol, (3b)-
9. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol
10. (3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-ol
11. 4-androstadienol
12. Unii-dtw1nj7ijh
13. Fasedienol [inn]
14. Aloradine [who-dd]
15. Ph94b
16. Androsta-4,16-dien-3beta-ol
17. Schembl4075431
18. Androsta-4,16-diene-3beta-ol
19. Dtxsid901032322
20. (3b)-androsta-4,16-dien-3-ol
21. Yaa06206
22. Mfcd00271236
23. Zinc34031047
24. Akos028109412
25. As-60043
26. Androsta-4,16-dien-3-ol, (3.beta.)-
27. Hy-145567
28. Cs-0376082
29. Q20707597
| Molecular Weight | 272.4 g/mol |
|---|---|
| Molecular Formula | C19H28O |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 0 |
| Exact Mass | 272.214015512 g/mol |
| Monoisotopic Mass | 272.214015512 g/mol |
| Topological Polar Surface Area | 20.2 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 476 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Intended for the acute treatment of social phobia.
Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptors location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.
Absorption
Absorbed following nasal administration.
There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.
Drugs in Development
Details:
PH94B (fasedienol) is a first-in-class, rapid-onset investigational pherine nasal spray. It is being evaluated for the acute treatment of social anxiety disorder.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for Social Anxiety Disorder
Details : PH94B (fasedienol) is a first-in-class, rapid-onset investigational pherine nasal spray. It is being evaluated for the acute treatment of social anxiety disorder.
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Details:
PH94B (fasedienol) is a first-in-class, rapid-onset investigational pherine nasal spray. It is being evaluated for the acute treatment of social anxiety disorder.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vistagen Initiates PALISADE-3 Study of Fasedienol for Social Anxiety Disorder Treatment
Details : PH94B (fasedienol) is a first-in-class, rapid-onset investigational pherine nasal spray. It is being evaluated for the acute treatment of social anxiety disorder.
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2024
Details:
Vistagen intends to use the proceeds for research and development associated with development of its product candidates, including its Phase 3 program for fasedienol, an investigational neuroactive pherine nasal spray, for anxiety in adults with social anxiety disorder.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: BVF Partners
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BVF Partners
Deal Size : $100.0 million
Deal Type : Public Offering
Vistagen Announces Pricing of $100 Million Underwritten Offering
Details : Vistagen intends to use the proceeds for research and development associated with development of its product candidates, including its Phase 3 program for fasedienol, an investigational neuroactive pherine nasal spray, for anxiety in adults with social a...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 02, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons ...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons ...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 07, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons ...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2023
Details:
PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (fasedienol) is a pherine nasal spray that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons ...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2023
Details:
Through the acquisition, Vistagen owns all intellectual property rights to PH94B (aloradine), in Phase 3 development for SAD and Phase 2 development for AjDA, and PH10, in clinical development for MDD, as well as three additional candidates in earlier stages of development.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: VistaGen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 02, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : VistaGen Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
Details : Through the acquisition, Vistagen owns all intellectual property rights to PH94B (aloradine), in Phase 3 development for SAD and Phase 2 development for AjDA, and PH10, in clinical development for MDD, as well as three additional candidates in earlier st...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2023
Details:
PH94B (aloradine) is a rapid-onset investigational pherine nasal spray that regulates olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (aloradine) is a rapid-onset investigational pherine nasal spray that regulates olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic ANS, without systemic distribution, potentiation of GABA-A or direct a...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2023
Details:
PH94B (aloradine) is a first-in-class synthetic investigational neurosteroid developed from proprietary compounds called pherines. PH94B is a nasal spray administered at microgram-level doses and designed to achieve rapid-onset anti-anxiety, or anxiolytic, effects.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Brand Name: PH94B
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Lead Product(s) : Fasedienol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PH94B (aloradine) is a first-in-class synthetic investigational neurosteroid developed from proprietary compounds called pherines. PH94B is a nasal spray administered at microgram-level doses and designed to achieve rapid-onset anti-anxiety, or anxiolyti...
Brand Name : PH94B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
